Compare Stocks → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:ICOTFNASDAQ:MTFBOTCMKTS:NEVPFNASDAQ:NVUSNASDAQ:TRPX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeICOTFiCo Therapeutics$0.34$0.37$0.80▼$1.82$3.09M2.034,760 shsN/AMTFBMOTIF BIO PLC/S$0.11$0.10$0.08▼$11.50N/AN/AN/A867,698 shsNEVPFAbliva AB (publ)$0.01$0.01$0.01▼$0.02N/AN/AN/AN/ANVUSNovus Therapeutics$2.02+2.5%$13.23$4.50▼$27.32$2.90M2.0778,851 shs67,382 shsTRPXTherapix Biosciences$0.10$0.23$0.25▼$4.69$351KN/A1.59 million shs95,212 shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceICOTFiCo Therapeutics0.00%-12.66%-5.36%-13.49%-38.61%MTFBMOTIF BIO PLC/S0.00%0.00%0.00%0.00%0.00%NEVPFAbliva AB (publ)0.00%0.00%0.00%-50.00%0.00%NVUSNovus Therapeutics0.00%+25.48%-7.08%+8.24%-12.05%TRPXTherapix Biosciences0.00%0.00%0.00%0.00%0.00%The Gold Grab of the Century (Ad)When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationICOTFiCo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMTFBMOTIF BIO PLC/SN/AN/AN/AN/AN/AN/AN/AN/ANEVPFAbliva AB (publ)N/AN/AN/AN/AN/AN/AN/AN/ANVUSNovus TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATRPXTherapix BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceICOTFiCo TherapeuticsN/AN/AN/AN/AMTFBMOTIF BIO PLC/SN/AN/AN/AN/ANEVPFAbliva AB (publ)N/AN/AN/AN/ANVUSNovus TherapeuticsN/AN/AN/AN/ATRPXTherapix BiosciencesN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookICOTFiCo TherapeuticsN/AN/AN/AN/A($0.07) per shareN/AMTFBMOTIF BIO PLC/SN/AN/AN/AN/AN/AN/ANEVPFAbliva AB (publ)N/AN/AN/AN/A$0.04 per shareN/ANVUSNovus TherapeuticsN/AN/AN/AN/A$13.13 per shareN/ATRPXTherapix BiosciencesN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateICOTFiCo Therapeutics-$1.11M-$0.40N/A∞N/AN/AN/A-288.85%N/AMTFBMOTIF BIO PLC/SN/AN/A0.00∞N/AN/AN/AN/AN/ANEVPFAbliva AB (publ)-$8.45MN/A0.00∞N/AN/A-63.75%-57.93%N/ANVUSNovus Therapeutics-$16.01M-$21.58N/AN/AN/AN/A-133.49%-30.52%N/ATRPXTherapix Biosciences-$4.79MN/A0.00∞N/AN/AN/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthICOTFiCo TherapeuticsN/AN/AN/AN/AN/AMTFBMOTIF BIO PLC/SN/AN/AN/AN/AN/ANEVPFAbliva AB (publ)N/AN/AN/AN/AN/ANVUSNovus TherapeuticsN/AN/AN/AN/AN/ATRPXTherapix BiosciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioICOTFiCo TherapeuticsN/A0.720.72MTFBMOTIF BIO PLC/SN/AN/AN/ANEVPFAbliva AB (publ)N/A6.606.60NVUSNovus TherapeuticsN/A18.7818.78TRPXTherapix BiosciencesN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipICOTFiCo TherapeuticsN/AMTFBMOTIF BIO PLC/SN/ANEVPFAbliva AB (publ)N/ANVUSNovus TherapeuticsN/ATRPXTherapix Biosciences14.32%Insider OwnershipCompanyInsider OwnershipICOTFiCo TherapeuticsN/AMTFBMOTIF BIO PLC/SN/ANEVPFAbliva AB (publ)N/ANVUSNovus Therapeutics2.20%TRPXTherapix BiosciencesN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableICOTFiCo TherapeuticsN/A9.05 millionN/ANot OptionableMTFBMOTIF BIO PLC/S7N/AN/ANot OptionableNEVPFAbliva AB (publ)8N/AN/ANot OptionableNVUSNovus Therapeutics71.44 millionN/ANot OptionableTRPXTherapix Biosciences93.51 millionN/ANot OptionableICOTF, NEVPF, MTFB, TRPX, and NVUS HeadlinesSourceHeadlineAnixa Biosciences Stock (NASDAQ:ANIX), Analyst Ratings, Price Targets, Predictionsbenzinga.com - December 12 at 5:48 AMSagimet Biosciences Inc (SGMT)investing.com - August 23 at 7:29 AMPBIO Pressure BioSciences, Inc.seekingalpha.com - August 1 at 3:24 PMCannabis, Coats, and Social Media: The Good, Bad, and Ugly of 2017's IPOsthestreet.com - January 19 at 7:59 PMCompany DescriptionsiCo TherapeuticsOTCMKTS:ICOTFSatellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.MOTIF BIO PLC/SNASDAQ:MTFBMotif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.Abliva AB (publ)OTCMKTS:NEVPFAbliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.Novus TherapeuticsNASDAQ:NVUSNovus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.Therapix BiosciencesNASDAQ:TRPX Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
